Zydus gets USFDA final approval for Imatinib Mesylate Tablets
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. (US RLD: Gleevec® Tablets)
This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.
The group now has 285 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here